Journal article Open Access

Jak3, severe combined immunodeficiency, and a new class of immunosuppressive drugs

Pesu, Marko; Candotti, Fabio; Husa, Matthew; Hofmann, Sigrun R.; Notarangelo, Luigi D.; O'Shea, John J.

Dublin Core Export

<?xml version='1.0' encoding='utf-8'?>
<oai_dc:dc xmlns:dc="" xmlns:oai_dc="" xmlns:xsi="" xsi:schemaLocation="">
  <dc:creator>Pesu, Marko</dc:creator>
  <dc:creator>Candotti, Fabio</dc:creator>
  <dc:creator>Husa, Matthew</dc:creator>
  <dc:creator>Hofmann, Sigrun R.</dc:creator>
  <dc:creator>Notarangelo, Luigi D.</dc:creator>
  <dc:creator>O'Shea, John J.</dc:creator>
  <dc:description>Summary:  The recent elucidation of the multiple molecular mechanisms underlying severe combined immunodeficiency (SCID) is an impressive example of the power of molecular medicine. Analysis of patients and the concomitant generation of animal models mimicking these disorders have quickly provided great insights into the pathophysiology of these potentially devastating illnesses. In this review, we summarize the discoveries that led to the understanding of the role of cytokine receptors and a specific tyrosine kinase, Janus kinase 3 (Jak3), in the pathogenesis of SCID. We discuss how the identification of mutations of Jak3 in autosomal recessive SCID has facilitated the diagnosis of these disorders, offered new insights into the biology of this kinase, permitted new avenues for therapy, and provided the rationale for a generation of a new class of immunosuppressants.</dc:description>
  <dc:title>Jak3, severe combined immunodeficiency, and a new class of immunosuppressive drugs</dc:title>
Views 208
Downloads 269
Data volume 1.1 GB
Unique views 203
Unique downloads 263


Cite as